Appearance
Your Playbook
What you have, what's working, what needs fixing. Every weakness here is something a competitor already knows.
VARIPULSE: The Honest Assessment
The Turnaround Story
At ~40,000 procedures, VARIPULSE has completed the transition from "small-sample, post-recall product" to "category-leading safety profile." The per-procedure rates are no longer unreliable — they're the best in PFA.
| Metric | VARIPULSE | FARAPULSE | PulseSelect |
|---|---|---|---|
| Deaths per 10K | 0.75 | 1.8 | 3.7 |
| Mfg defects per 10K | 3.0 | 5.7 | 44.3 |
| Post-correction stroke rate | 0.22% | 0.1% (MANIFEST) | — |
| Same-day discharge | 87.9% | — | — |
The Deaths
Three MAUDE death reports for two patients (Nov-Dec 2025). No device returned in either case.
Patient 1 (Nov 28, 2025): Pericardial effusion + pulmonary hemorrhage. Autopsy: pulmonary vein damage from aggressive CPR. Key detail: effusion started during CTI ablation with QDOT (RF), before VARIPULSE was used at all. Investigation concluded: "No device malfunction reported... death cannot be completely dissociated from VARIPULSE." Two MAUDE records filed for the same event.
Patient 2 (Dec 5, 2025): Hemorrhagic stroke. Patient didn't wake from anesthesia. 20 PFA ablations, all within PVs. Note: "correct catheter settings were NOT selected on the generator." Internal corrective action opened.
Current J&J Public Messaging
J&J's published materials cite cohort-specific safety data, not blanket "zero deaths" claims:
- "No strokes, deaths, or device-related hospitalizations" — VARIPURE substudy (200 patients, ESC 2025)
- "0.6% primary adverse rate with no strokes" — VARIPURE (791 patients, ESC 2025)
- "0.22% neurovascular event rate" — across 6,811 post-IFU patients (2026 AF Symposium)
- "Deaths: 0 cases" — VARISURE physician survey (850 procedures)
These cohort-specific claims are now outdated by the two patient deaths. The shift to rate-based messaging is both necessary and stronger.
| Current Claim | Update Needed | New Message |
|---|---|---|
| "No deaths" in select cohorts | Outdated by Nov-Dec 2025 deaths | "Best death rate in PFA — 0.75 per 10K. All investigated." |
| "Lowest death rate" | Now valid at 40K procedures. | 0.75 per 10K vs 1.8 FARAPULSE. Lead with this. |
| "Best manufacturing quality" | Now valid at 40K procedures. | 3.0 per 10K vs 5.7 FARAPULSE. |
The Reporting Gap Is Closed
The "7x reporting gap" that made all VARIPULSE per-procedure metrics unreliable is gone:
| Old (3K procs) | Current (40K procs) | |
|---|---|---|
| MAUDE reports per 1K procedures | 87 | 6.5 |
| FARAPULSE comparison | 12 (7.2x gap) | 4.8 (1.35x gap) |
At 6.5 vs 4.8 reports per 1K procedures, the reporting rates are comparable. Per-procedure claims are now defensible.
What VARIPULSE Can Claim Honestly
- Lowest death rate in PFA (0.75 per 10K vs 1.8 FARAPULSE, 3.7 PulseSelect)
- Lowest mfg defect rate (3.0 per 10K vs 5.7 FARAPULSE, 44.3 PulseSelect)
- 100% investigation rate — every death fully documented with follow-up
- Post-correction stroke rate: 0.22% in 6,811 patients
- 87.9% same-day discharge (VARISURE, 850 procedures)
- Only PFA with full 3D mapping (CARTO integration)
- VA institutional adoption post-recall — $2M+ in VA procurement contracts (H2 2025)
QDOT MICRO: The RF Anchor
~60% of EP ablations are PFA-appropriate. The other 40% — complex VT, atypical flutter, redo procedures — needs RF. Only J&J covers both.
The pitch: "PFA handles 60% of cases. We handle 100%."
QDOT/ThermoCool Fleet Status
| Device | FDA Events | Deaths | Mfg Defects | Design Flaws |
|---|---|---|---|---|
| ThermoCool SmartTouch SF | 609 | 25 | 50 | 5 |
| QDOT MICRO (all variants) | 587 | 20 | 31 | 9 |
| SmartTouch (legacy) | 167 | 0 | 0 | 10 |
| ThermoCool SF variants | 211 | 6 | 23 | 1 |
PEBAX Watch
PEBAX polymer separation — catheter sheath pulling apart from electrode. The combined event count across QDOT, ThermoCool, SmartTouch variants is substantial (1,574 events, 51 deaths). Same material, same factory, spanning multiple product generations.
Action: Quality engineering should quantify the trend by lot number and manufacturing date. The scale of events across the RF catheter fleet (50+ mfg defects in SmartTouch SF alone since Jan 2024) warrants proactive monitoring. A competitor referencing this pattern in an evaluation could be damaging.
CARTO: The Platform
50%+ US mapping share. 87 FDA adverse events, 4 design flaws, 2 deaths in two years.
Strengths:
- 20 years of workflow integration
- Most open platform post-injunction ($400-800/case savings with reprocessed catheters)
- Only 4 design flaws vs 32 for Affera — lowest in category
Threats:
- Affera eliminates the need for a separate mapping purchase (300%+ growth)
- ASCs won't buy $500K systems for simple PFA (CMS just opened the door)
- BSC's Faraflex will add integrated map+ablate to FARAPULSE
- BSC's Farapoint adds focal PFA capability (FDA Jan 2026)
- Abbott Volt gives EnSite X a PFA anchor
Defense: CARTO wins where complexity matters. Concede simple AF in cost-sensitive settings. Defend everything else.
Omnypulse: The Pipeline
30-patient pilot (OMNY-AF) presented at 2026 AF Symposium:
| Metric | Result |
|---|---|
| Acute procedural success | 100% |
| Procedure-related adverse events | 0 |
| MRI-detected cerebral lesions | 0 |
| Zero-fluoroscopy procedures | 56.7% |
| 12-month primary effectiveness | 90% |
- 12 mm large-tip focal catheter with contact-force sensing
- Bipolar, biphasic pulse delivery via TRUPULSE generator
- Complementary to VARIPULSE (point-by-point vs multi-electrode)
- OMNY-AF enrolling up to 440 patients across 40+ sites (US + Australia)
- J&J plans to release a new PFA catheter every year through end of decade
Strategic value: The zero cerebral lesion finding directly counters the VARIPULSE stroke narrative. Accelerating this program strengthens the entire J&J PFA story.
J&J also has a dual-energy SmartTouch SF catheter (PFA + RF switching) that received CE mark in January 2025 — adding another coverage option for the PFA+RF portfolio.
Portfolio Strategy
Only J&J covers both slices. BSC has PFA but no competitive RF. Medtronic has Affera (dual-energy) but no standalone RF workflow. Abbott has both but is a year behind on PFA data.
| Product | Role | What To Say | Risk To Monitor |
|---|---|---|---|
| VARIPULSE | PFA | Best death rate, best mfg quality, full mapping | Design flaw rate (7.8 per 10K), no registry |
| QDOT MICRO | RF | "We cover 100% of cases" | PEBAX quality trend (1,574 events across fleet) |
| CARTO | Mapping | Open + proven, 20 years, fewest design flaws | Affera displacement, ASC gap, Faraflex |
| Omnypulse | Pipeline | "90% at 12 months, zero cerebral lesions" | Years from approval |
One sentence: "The only EP company with the best PFA death rate, the only RF catheter, and the mapping system in 50% of US labs."
FDA adverse event data (2.99M events), VARISURE Safety Survey (850 procs), OMNY-AF pilot (30 patients), ESC 2025 post-IFU data, VA procurement (USAspending.gov). See Method.